#Stimulants

Millions of children in the United States are diagnosed with attention-deficit hyperactivity disorder (ADHD), and the vast majority are prescribed stimulant medications such as Ritalin and Adderall. However, a new wave of research reported by NPR and detailed in The New York Times Magazine raises pressing questions about the effectiveness and long-term consequences of these treatments, as well as the very nature of ADHD itself (NPR, 2025).

The U.S. Centers for Disease Control and Prevention (CDC) revealed last year that more than 11% of American children had received an ADHD diagnosis—a record high, and a dramatic increase from the early 1990s figure of just 2 million. In 14-year-old boys, the rate soars to 21%. These statistics portray a nation deeply invested in identifying—and medicating—children with ADHD. But why are diagnoses rising, and are treatments truly serving those diagnosed?

A comprehensive new analysis, published in The Lancet Psychiatry, underscores that medications prescribed for attention-deficit/hyperactivity disorder (ADHD) generally induce minor impacts on cardiovascular health, mostly characterized by slight elevations in heart rate and blood pressure. Conducted by an international team led by the University of Southampton, this large study evaluated data from 102 clinical trials involving over 22,702 participants globally, comparing both stimulant and non-stimulant medications used to treat ADHD. The news from this research provides a balanced view, suggesting that while there are small cardiovascular effects, the broader benefits of these medications often outweigh such risks.